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Abstract
Background: Critical illness is characterized by a loss of commensal flora and an overgrowth of potentially
pathogenic bacteria, leading to a high susceptibility to nosocomial infections. Probiotics are living non-pathogenic
microorganisms, which may protect the gut barrier, attenuate pathogen overgrowth, decrease bacterial
translocation and prevent infection. The purpose of this updated systematic review is to evaluate the overall
efficacy of probiotics and synbiotic mixtures on clinical outcomes in critical illness.
Methods: Computerized databases from 1980 to 2016 were searched. Randomized controlled trials (RCT) evaluating
clinical outcomes associated with probiotic therapy as a single strategy or in combination with prebiotic fiber
(synbiotics). Overall number of new infections was the primary outcome; secondary outcomes included mortality,
ICU and hospital length of stay (LOS), and diarrhea. Subgroup analyses were performed to elucidate the role of
other key factors such as probiotic type and patient mortality risk on the effect of probiotics on outcomes.
Results: Thirty trials that enrolled 2972 patients were identified for analysis. Probiotics were associated with a
significant reduction in infections (risk ratio 0.80, 95 % confidence interval (CI) 0.68, 0.95, P = 0.009; heterogeneity
I2 = 36 %, P = 0.09). Further, a significant reduction in the incidence of ventilator-associated pneumonia (VAP) was
found (risk ratio 0.74, 95 % CI 0.61, 0. 90, P = 0.002; I2 = 19 %). No effect on mortality, LOS or diarrhea was observed.
Subgroup analysis indicated that the greatest improvement in the outcome of infections was in critically ill patients
receiving probiotics alone versus synbiotic mixtures, although limited synbiotic trial data currently exists.
Conclusion: Probiotics show promise in reducing infections, including VAP in critical illness. Currently, clinical
heterogeneity and potential publication bias reduce strong clinical recommendations and indicate further high
quality clinical trials are needed to conclusively prove these benefits.
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Background
Critical illness is characterized by a loss of commensal
flora and an overgrowth of potentially pathogenic bac-
teria, leading to a high susceptibility to acquired nosoco-
mial infections [1, 2]. Further, sepsis following infection
is still a leading cause of death worldwide [3]. The U.S.
Centers for Disease Control indicates death rates from
critical illness/sepsis have increased at a rate greater than
any other common cause of mortality in the last year for
which data were available [4]. Thus, therapies to reduce
the risk and incidence of infection and sepsis in critical
illness are urgently needed.
According to the World Health Organization and the
Food and Agriculture Organization, probiotics are living
non-pathogenic microorganisms, which have demon-
strated well-documented beneficial health effects admin-
istered in optimum amounts in the prevention and
treatment of several disease states [5]. So far, several
mechanisms by which probiotics may exert beneficial
effects have been described, including modification of
the gut flora by inducing host cell antimicrobial pep-
tides, release of antimicrobial factors, suppression of the
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immune cell proliferation, stimulation of mucus and IgA
production, anti-oxidative activity, inhibition of epithelial
cell nuclear factor kappa B activation, and other poten-
tially vital gut epithelial barrier protective effects [6–8].
As the gut is hypothesized to play a central role in the
progression of critical illness, sepsis and multiple organ
dysfunction syndrome [9], maintenance of the gut bar-
rier and a healthy gut microbiome, potentially via re-
introduction of commensal bacteria (probiotic therapy),
may be essential to optimizing outcomes in critically ill
patients.
According to current literature, the efficacy of probio-
tics in the prevention of infectious complications has
been extensively evaluated in many animal studies and
clinical trials in heterogenous intensive care unit (ICU)
patient populations. These studies suggest that probio-
tics may reduce the incidence of infection, particularly
ventilator-associated pneumonia (VAP) [10], which is a
common serious complication in intubated, mechanically
ventilated patients [11]. Nonetheless, the effect of probio-
tics on the prevention of VAP still remains controversial
and inconclusive [12–17]. In fact, its effect depends on the
patient population and the probiotic strain studied. Des-
pite the outcome benefits of probiotics therapy, recent
guidelines have been unable to make a definitive recom-
mendation for the routine use of probiotics in ICU pa-
tients. To date, these guidelines have suggested the use of
probiotic therapy in select medical and surgical patient
populations in whom trials have documented safety and
clinical benefits [18, 19].
Over the last few years, several systematic reviews and
meta-analyses have evaluated the effects of probiotics in
critically ill patients [12–17]. In 2012, after aggregating
11 trials that reported on infections [14], we demon-
strated that probiotics may reduce infections, including
the incidence of VAP, although the effect on VAP was
not statistically significant given the available data.
Moreover, probiotics were associated with a trend
toward reduced ICU mortality, but did not influence
hospital mortality. Since our last systematic review and
meta-analyses, seven new trials of probiotic therapy have
been published [20–26]. Further, to date, no recent
meta-analysis has examined the effect of probiotic versus
synbiotic (probiotic and prebiotic fiber) therapy. Finally,
a Canadian survey [27] on the use of probiotics as a
prophylactic strategy for VAP showed that most Canad-
ian ICU pharmacists have used probiotics at least once,
although routine use is considered controversial and
considerable practice variability exists. Thus, any in-
creased understanding that the newly published trials can
yield will be vital to clarifying clinical probiotic use in the
ICU and areas in need of future research focus.
Therefore, as probiotic use in the ICU remains wide-
spread and controversial, current guidelines are not
conclusive, and with a significant number of new trials
of probiotic use published recently we conducted a com-
prehensive systematic review and meta-analysis of pro-
biotic and synbiotic use in critically ill patients. Our aim
was to elucidate the overall efficacy of probiotics, as a
single strategy or in combination with fiber therapy
(synbiotics) on relevant clinical outcomes, particularly
infection and VAP, in adult critically ill patients.
Methods
Search strategy and study identification
A literature search was conducted in MEDLINE, Embase,
CINAHL, the Cochrane Central Register of Controlled
Trials and the Cochrane Database of Systematic Reviews
to identify all relevant randomized controlled trials (RCTs)
published between 1980 and April 2016. The literature
search used broad search terms containing “randomized,”
“clinical trial,” “nutrition support,” “enteral nutrition”,
“probiotics,” and “synbiotics”. No language restrictions
were applied. Personal files and reference lists of rele-
vant review articles were also reviewed.
Eligibility criteria
We included trials with the following characteristics:
1. Type of study: randomized controlled parallel group
trials
2. Population: adult (≥18 years of age) critically ill
patients. If the study population was unclear, we
considered a mortality rate higher than 5 % in the
control group to be consistent with critical illness
3. Intervention: Probiotics alone or associated with
prebiotics (synbiotics) compared to a placebo
4. Outcomes: pre-specified clinical outcomes in ICU
patients such as infectious complications, VAP,
mortality, ICU and hospital length of stay (LOS),
and diarrhea
We excluded trials that reported only nutrition, bio-
chemical, metabolic, or immunologic outcomes. Data
published in abstract form were included only if add-
itional information about the study design was obtained
from the authors. The methodological quality of the in-
cluded trials was assessed in duplicate by two reviewers
independently using a data abstraction form with a scor-
ing system from 0 to 14 according to the following
criteria:
1. The extent to which randomization was concealed
2. Blinding
3. Analysis based on the intention-to-treat (ITT)
principle
4. Comparability of groups at baseline
5. Extent of follow up
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6. Description of treatment protocol
7. Co-interventions
8. Definition of clinical outcomes
Consensus between both reviewers on the individual
scores of each of the categories was obtained. We
attempted to contact the authors of included studies
and requested additional information not contained in
published articles. We designated studies as level I if
all of the following criteria were fulfilled: concealed
randomization, blinded outcome adjudication and an
ITT analysis, all which are the strongest methodo-
logical tools to reduce bias. A study was considered as
level II if any one of the above-described characteristics
were unfulfilled.
Data synthesis
All analyses, except the test for asymmetry, were con-
ducted using RevMan 5.3 (Cochrane IMS, Oxford,
UK) with a random effects model. We combined data
from all trials to estimate the overall weighted mean
difference (WMD) with 95 % confidence intervals for
LOS data the pooled risk ratio (RR) with 95 % confi-
dence intervals (CIs) for the incidence of infections
and mortality, and diarrhea. WMDs were estimated
by the inverse variance approach and pooled RRs
were calculated using the Mantel-Haenszel estimator.
The random effects model of DerSimonian and Laird
was used to estimate variances for the Mantel-
Haenszel and inverse variance estimators [28]. RRs
were undefined and excluded for studies with no
event in either arm. Heterogeneity was tested by a
weighted Mantel-Haenszel χ2 test and quantified by
the I2 statistic as implemented in RevMan. Differences
between subgroups were analyzed using the test of
subgroup differences described by Deeks et al., and
the results expressed using the P values. We consid-
ered P <0.05 to be statistically significant and P <0.10
as an indicator of trends. Funnel plots were used to
assess the possibility of publication bias and the Egger
regression test was used to measure funnel plot asym-
metry [29].
Clinical outcomes
Overall infections were the primary outcome for this
meta-analysis. Secondary outcomes were VAP, mortality,
ICU and hospital LOS, and finally diarrhea. We used
definitions of infections as defined by the authors in
their original articles. From all trials, we combined hos-
pital mortality where reported. Mortality specified at
either 28 days or 90 days was not considered as ICU or
hospital mortality, respectively. Nonetheless, if the
mortality time frame was not specified as either ICU or
hospital, it was presumed to be the later.
Subgroup analysis
We utilized predefined subgroup analyses to assess a
number of possible influences on the effect of probiotic
supplementation on clinical outcomes, and thus to
explore the possible causes of heterogeneity. On the
basis that the higher the daily dose the greater the effect,
we first examined trials that administered a high dose
of probiotics defined as >5 × 109 colony-forming units
(CFU)/day vs. lower dose probiotics defined as <5 ×
109 CFU/day. Second, we compared the results of RCTs
that administered Lactobacillus plantarum as probiotic
therapy vs. no L. Plantarum, and compared trials using
Lactobacillus rhamnosus strain GG (LGG) vs. those ad-
ministering other non-LGG strains.
Moreover, based on a larger treatment effect in those
more seriously ill patients with higher risk of death, we
compared studies including patients with higher mortal-
ity vs. lower mortality. Mortality was considered to be
high or low based on whether it was greater or less than
the median control group mortality of all the trials. Tri-
als of higher quality, defined as those with a methodo-
logical score equal to or higher than the median quality
score, may demonstrate a lower treatment effect.
Results
Study identification and selection
A total of 79 relevant citations were identified from the
search of computerized bibliographic databases and a re-
view of reference lists from related articles. Of these, we
excluded 49 due to the following reasons: 21 trials did not
include ICU patients (mostly surgical patients); 12 articles
were systematic reviews and meta-analyses; 4 trials were
published as an abstract and we were unable to obtain the
data from the authors to complete our data abstraction
process; 5 articles were duplicates of included trials; 3
studies did not evaluate clinical outcomes; 2 trials tested
multiple interventions; 1 study was not a RCT, and finally
1 study administered probiotics as oral swabs.
Finally, 30 RCTs [10, 20–26, 30–51] met our inclusion
criteria and were included, covering a total of 2972 patients
(see Tables 1 and 2). The reviewers reached 100 % agree-
ment on the inclusion of the trials. The mean methodo-
logical score of all trials was 9, whereas the median value
was 9.5 on a maximum of 14 (range 5–13). Randomization
was concealed in 9/30 trials (30 %), ITT analysis was per-
formed in 18/30 trials (60 %), and double blinding was
done in 20/30 of the studies (67 %). There were five level-I
studies and 25 level-II studies. The details of the methodo-
logical quality of the individual trials are shown in Table 1.
Primary outcome: infections
Overall effect on new infections
Aggregating the results of the 14 trials reporting overall
infections, probiotics were associated with a significant
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Table 1 Randomized studies evaluating probiotics in critically ill patients
Study Population Methods score Type of probiotic/intervention
Delivery vehicle Intervention/dose/duration Control







EN tube EN (unknown) + Ultra-Levure
(Saccharomyces boulardii),
1010/1 L solution for 11–21 days
EN (unknown) + placebo
(sterile solution)







NG tube EN (Polydiet or Nutrigil) +
Saccharomyces boulardi
500 mg QID for 8-28 days
EN (Polydiet or Nutrigil) + placebo
3 Heimburger 1994 [32] Mixed ICU patients:







EN tube EN (standard) + 1 g of Lactinex
(Lactobacillus acidophilus and
Lactobaccilus bulgaricus) 2 × 106
TID for 5–10 days
EN (standard) + placebo
(0.5 g dextrose + 0.5 g lactose)







EN tube EN (unknown) + Saccharomyces
boulardii
500 mg QID for 21 days or
until EN stopped
EN (unknown) + placebo
(powder)







NJ tube EN (Nutrison fiber) + fermented
oatmeal formula with Lactobacillus
plantarum 299 10 9 BID and fiber for
7 days
EN (Nutrison fiber) + heat-killed
Lactobacillus plantarum 299
BID + fiber (non-viable)







Oral or NG tube EN or PN + Trevis™ 1 capsule TID +
7.5 g Raftilose (oligofructose)
BID until hospital discharge
EN or PN + placebo
(powdered sucrose capsules)







NR EN + synbiotics (4 types of
probiotics + 4 types of unspecified
prebiotics) for 21 days
EN + 4 types of prebiotics











EN + Lactobacillus plantarum 299v,
109/day 50 ml every 6 h × 3 days
then 25 ml every 6 h until ICU
discharge
EN (Impact or Nutrodrip fiber).
Some patients needed PN







Oral, NJ tube EN or PN + Proviva, (oatmeal and
fruit drink) 5 × 107 CFU/ml of
L. plantarum 299 v × 500 mls until
hospital discharge or beyond










Table 1 Randomized studies evaluating probiotics in critically ill patients (Continued)
10 Kotzampassi 2006 [39] Patients with multiple











EN or PN + Synbiotic 2000 Forte
1011, 1 sachet/day for 15 days
until ICU discharge
EN or PN + placebo (maltodextrin),
mixed in tap water







for VSL # 3; Yes for bacteria
sonicates
NG tube Jevity Plus (EN) (10 g
fructooligosaccharides/1000 mL
and 12 g of soluble and
insoluble fiber blend) +
VSL # 3, 1 package BID,
9 × 1011 /day for 7 days until
ICU discharge or EN
discontinuation
Jevity Plus + placebo








Given enterally Jinshuangqi (bifidobacteria,
lactobacillus and streptococcus)












NJ tube EN (Nutricion fiber) + Synbiotic
2000, 4 × 1010 CFU for 7 days
EN (Nutricion fiber) + 10 g
plant fibers ((2.5 g each of
Betaglucan, inulin, pectin and
resistant starch) (prebiotics)
BID for at least 2 days









NG tube or oral
(after tube removal)
Lactobacillus casei rhamnosum,
109 CFU BID until ICU discharge
Placebo (growth medium
never exposed to bacteria).
15 Besselink 2008 [43] Patients with severe acute








NJ tube or oral EN (Nutrison multifiber)
+ Ecologic 641 1010 CFU BID
for 28 days
EN (Nutrison multifiber) + placebo
(cornstarch +maltodextrins)
16 Klarin 2008 [45] ICU patients from 5 ICUs,









enteral feeds NG tube
299 Lactobacillus plantarum,
8 × 108 CFU/ml given as 6 × 100 ml
doses every 12 h and after 50 ml
given BID until ICU discharge
Same oatmeal gruel mixed with
lactic acid








NJ or OG (orogastric)
tube
EN (Nutrition Energy) +
Synbiotic 2000 FORTE
4 × 1011 species/sachet
BID for 28 days or ICU discharge










Table 1 Randomized studies evaluating probiotics in critically ill patients (Continued)
18 Barraud 2010 [47] Mechanically ventilated ICU








NG tube EN (Fresubin) + Ergyphilus
2 × 1010 per capsule + potato
starch 5 capsules/day for 28 days
EN (fresubin) + placebo capsules
(excipient of potato starch)









EN (routine care) + Lactobacillus
rhamnosus GG, 2 × 109 BID as
lubricant and mixed with water
until extubation
EN (routine care) + inert plant
starch inulin (prebiotic) BID as
lubricant and mixed with water








NG or NJ tube EN (Standard) + VSL #3 mixed in
nutritional supplement (Sustagen),
BID until hospital discharge
EN (Standard) + placebo
mixed in nutritional
supplement (Sustagen), BID








NG tube EN (Standard) + Culturelle
(Lactobacillus rhamnosus GG),
1010 species/capsule
+280 mg inulin powder for 7 days
EN (Standard) + Raftiline, gelatin
capsule with 280 mg inulin
powder (prebiotic)








Oral, NJ or NG EN (standard) or oral
4 sachets each 2.5 × 109
Lactobacillus acidophilus, Bifidobacterium
longus, Bifidobacterium bifidum &
Bifidobacterium infantalis+ 25 gms
fructose for 7 days
EN (Standard) + placebo









NG tube EN (standard)
total of 109 bacteria i.e.,
7 sachets each 0.5 × 108Bifidobacterium
longum, 0.5 × 1071 Lactobacillus
bulgaricus and 0.5 × 107Streptococcus
thermophilus for 21 days
EN (standard)








EN EN + bifidobacterium, 4 capsules
(each 210 mg, 2.604 × 109) every
12 h, given through nasal gastric
tube. Total dose per day 20.832 × 109
EN







NG tube EN + 1 × 109 bacteria of viable
probiotics (Golden Bifid, 3.5 g 3 times











Table 1 Randomized studies evaluating probiotics in critically ill patients (Continued)
26 Wang 2013 [22] Severe acute pancreatitis








SBFT EN (standard) + capsules 0.5 g TID
containing Bacillus subtilis and
Enterococcus faecium (5.0 × 107
Bacillus subtilis and 4.5 × 108
Enterococcus faecium per 250 g
capsule). Unclear timeframe.
EN (standard)
27 Lopez de Toro 2014
[23]














coliformes × 7 days (max 4.8 ×
109 UFC/ml).
EN and PN
28 Sanaie 2014 [24] Critically ill pts, SIRS, expected







NG tube EN (standard) + 2 sachets VSL#3
BID × 7 days.






ventilation at least 72 h and







EN 80 ml of 8 × 109 cfu of Lactobacillus
casei (Shirota strain) (Yakult) for
oral care after the standard oral
care once daily
An additional 80 ml of the product
was given via enteral feeding once
daily for 28 days or when their
endotracheal tubes were removed
EN (standard) + oral care with
2 % chlorhexidine solution
4 times per day
30 Zeng 2016 [26] Critically ill patients,
expected to receive
mechanical







NG tube 1 capsule (Medilac-S, China) 0.5 g
three times daily. Each probiotic
capsule contained
active Bacillus subtilis and Enterococcus
faecalis at a concentration of 4.5 ×
109 /0.25 g and 0.5 × 109/0.25 g,
respectively
EN (standard)
CFU colony forming units, C.Random concealed randomization, EN enteral nutrition, FOS fructooligosaccharides, NG nasogastric, NJ nasojejunal, NR not reported, OG orogastric, ITT intention to treat, SIRS, systemic
inflammatory response syndrome, VAP ventilator-associated pneumonia, BID twice daily. Trevis™: 1 capsule = Lactobacillus acidophilus La5, Bifidobacterium lactis Bb12, Streptococcus thermophilus, Lactobacillus bulgaricus,
4 × 109/total; Synbiotic 2000 Forte: 1011 CFU each of Pediococcus pentoseceus 5-33:3, Leuconostoc mesenteroides 32-77:1, L. paracasei ssp paracasei 19, L. plantarum 2362, and 2.5 g each of inulin, oat bran, pectin and
resistant starch; Ergyphilus: 1010Lactobaccilus rhamnosus GG, Lactobacillus casei, L. acidophilus, Bifidobacterium bifidus; VSL # 3: >1010Bifidobacterium longum, Bifidobacterium breve, >1010/gBifidobacterium infantis, >1011/g
L. acidophulus, L. plantarum, L. casei, L. bulgaris, and Streptococcus thermophiles; Jinshuangqi: B. longum >107 CFU, L. bulgaricus >106 CFU, and S. Thermophilus >106 CFU; Ecologic 641: L. acidophilus, Lactobacillus salivarius,
Lactococcus lactis, B. bifidus, and Bifidobacterium lactis; Synbiotic 2000: 1010 CFU each of P. pentoseceus 5-33:3, Leuconostoc mesenteroides 32-77:1, L. paracasei ssp paracasei 19, L. plantarum 2362, and 2.5 g each of










Table 2 Reported clinical outcomes in RCTs evaluating probiotics in critically ill patients
Study Mortality Infections Length of stay Diarrhea
Intervention Control Intervention Control Intervention Control Intervention Control












NR NR NR NR NR NR Diarrhea 5/16 (31) Diarrhea 2/18 (11)





























ICU 11.9 ± 13.1
Hospital
18.7 ± 13.5
ICU 9.0 ± 8.9
NR NR








NR NR NR NR








ICU 14.2 ± 10.6
Hospital
34.3 ± 15.4








ICU 5 (2–9) ICU 4 (2–7) NR NR
10 Kotzampassi 2006
[39]




















ICU 27.7 ± 15.2 ICU 41.3 ± 20.5 Diarrhea 5/35 (14) Diarrhea 10/30 (30)
11 Alberda 2007 [40] ICU 1/10 (10) ICU 1/9 (11) NR NR NR NR Diarrhea 1/10 (14) Diarrhea 2/9 (23)














Table 2 Reported clinical outcomes in RCTs evaluating probiotics in critically ill patients (Continued)


























14 Forestier 2008 [44] NR NR VAP 19/102 (19) VAP 21/106 (20) ICU 22.5 ± 20.6 ICU 19.7 ± 16.7 NR NR

















ICU 6.6 ± 17
Hospital
23.5 ± 25.9











C. difficile + fecal
samples 0/71




ICU 8.0 ± 5.4
Hospital
50.3 ± 75.2
ICU 11.6 ± 14
NR NR






































ICU 18.7 ± 12.4
Hospital
28.9 ± 26.4





19 Morrow 2010 [10] 12/68 (18) 15/70 (21) VAP 13/73 (18) VAP 28/73 (38) Hospital
21.4 ± 14.9
ICU 14.8 ± 11.8
Hospital
21.7 ± 17.4











5/20 (25) 3/25 (12) NR NR ICU 7.3 ± 5.7 ICU 8.1 ± 4 Diarrhea episodes/
pt/day 0.53 ± 0.54
Diarrhea episodes/
pt/day 1.05 ± 1.08














ICU 32.04 ± 24.46
Hospital
59.04 ± 33.92















ICU 4.94 ± 9.54
Hospital
9.69 ± 9.69











Table 2 Reported clinical outcomes in RCTs evaluating probiotics in critically ill patients (Continued)









ICU 6.8 ± 3.8 ICU 10.7 ± 7.3 NR NR





10.4 ± 3.9 (23)
Hospital
13.4 ± 5.2 (25)
NR NR




NR NR ICU 6.8 ± 3.8 (26) ICU 10.7 ± 7.3 (26) NR NR










NR NR NR NR































































BSI blood stream infection, ICU intensive care unit, NR not reported, RCT randomized control trial, UTI urinary tract infection, VAP ventilator associated pneumonia, N/A non-attributable, compl complications, MODS










reduction in infections (RR 0.80, 95 % CI 0.68, 0.95,
P = 0.009; heterogeneity I2 = 36 %, P = 0.09; Fig. 1).
Secondary outcomes
Ventilator associated pneumonia
Aggregating the data from 9 trials that reported VAP,
there was a significant reduction in the incidence of
VAP (RR 0.74, 95 % CI 0.61, 0.90, P = 0.002; I2 = 19 %,
P = 0.27; Fig. 2).
Overall effect on mortality
A total of 17 studies reported on hospital mortality.
When statistically aggregated, probiotic therapy did not
significantly affect mortality (RR 0.98, 95 % CI 0.82, 1.18,
P = 0.85; I2 = 0 %, Fig. 3). Moreover, probiotics did not
show any effect on ICU mortality (RR 0.90, 95 % CI
0.70, 1.17, P = 0.44; I2 = 0 %).
Overall effect on ICU length of stay
Aggregating the data from the 14 RCTs reporting on
ICU LOS, there were no significant differences between
the groups (weighted mean difference (WMD) -3.26,
95 % CI -7.82, 1.31, P = 0.16; I2 = 93 %, P < 0.00001).
Overall effect on hospital length of stay
Aggregating the data from the nine RCTs that reported
hospital LOS, there were no significant differences be-
tween the groups (WMD -0.58, 95 % CI -3.66, 2.50,
P = 0.71; I2 = 74 %, P < 0.00001).
Diarrhea
Aggregating the data from nine trials that reported on
diarrhea, probiotics had no effect (RR 0.97; 95 % CI 0.82,
1.15; P = 0.74; I2 5 %, P = 0.39; Fig. 4).
Antibiotic days
When we aggregated the data of four trials reporting on
antibiotic days, we found that probiotics were significantly
associated with a reduction in the duration of antibiotic
therapy (WMD -1.12, 95 % CI -1.72, -0.51, P = 0.0003;
I2 = 32 %, P = 0.22; Fig. 5).
Subgroup analysis
Probiotics daily dose
There were similar rates of infectious complications in
RCTs using high-dose probiotic therapy (n = 8 trials)
(0.87; 95 % CI 0.72–1.06; P =0.18; I2 = 43 %) and in those
using lower daily doses (n = 2 trials) RR 0.40; 95 % CI
0.11–1.50; P = 0.18; I2 = 48 %. The difference between
subgroups was not significant, P = 0.25).
L. plantarum vs. non L. plantarum
Subgroup analyses showed that four trials administering
L. plantarum, either alone or in combination with other
probiotics, were associated with a significant reduction
in overall infections (RR = 0.70, 95 % CI 0.50, 0.97; P =
0.03; I2 = 36 %). However, in the 10 trials that did not in-
clude L. plantarum, there was no significant effect on
overall infectious complications (RR = 0.88, 95 % CI
0.74,1.04; P = 0.15; I2 = 21 %). Test for subgroup differ-
ences between groups was not significant (P = 0.21).
L. rhamnosus GG vs. other probiotics
In two trials using LGG there was no significant effect
on reduction in infectious complications (RR 0.86; 95 %
CI 0.67–1.10; P = 0.22; I2 = 0 %). However, in 12 trials
that supplemented other probiotics there was a signifi-
cant reduction in overall infections (RR 0.77; 95 % CI
0.62–0.95; P = I2 = 45 %); P = 0.52 for the difference be-
tween groups.
Fig. 1 Effect of probiotics on overall infections (n = 14). CI confidence interval, M-H Mantel-Haenszel test
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Synbiotics vs. other strategies
In subgroup analyses of the four trials that administered
synbiotics there was no effect on infections (RR = 0.80,
95 % CI 0.49, 1.30, P = 0.36; I2 = 66 %, P = 0.03) (Fig. 6).
However, in 10 studies that administered probiotics alone
there was a significant reduction in the incidence of infec-
tions (RR 0.79, 95 % CI 0.68, 0.92, P = 0.002; I2 = 9 %, P =
0.36). The P value for subgroup differences was not
significant (P = 0.98). (Fig. 6).
Higher vs. lower mortality
The median hospital mortality rate of all the trials (or
ICU mortality when hospital mortality was not reported)
in the control group was 19 %. After aggregating nine
studies with a higher mortality rate, probiotics signifi-
cantly reduced the incidence of infections (RR 0.74; 95 %
CI 0.57, 0.96; P = 0.02; I2 = 58 %, P = 0.01) (Fig. 7). How-
ever, probiotics did not have an effect on infections in
the five studies with lower mortality (RR 0.85; 95 % CI
0.66, 1.11; P = 0.24; I2 = 23 %, P = 0.27). The test for sub-
group differences was not significant (P = 0.43) (Fig. 7).
Higher vs. lower methodological score
The median methodological score was 9.5. In six trials
with a higher score (≥9.5) there was no effect on infections
(RR 0.93; 95 % CI 0.76, 1.15; P = 0.51; I2 = 35 %, P = 0.17),
whereas in eight trials with a lower methodological score
(<9.5) there was a significant reduction in infectious com-
plications (RR 0.69, 95 % CI 0.57, 0.83, P < 0.0001; I2 =
0 %) (Fig. 8); the overall test for subgroup differences was
significant for these subgroups (P = 0.03).
Publication bias
There was indication that potential publication bias in-
fluenced the observed aggregated results. In fact, funnel
plots were created for each study outcome and the tests
Fig. 2 Effects of probiotics therapy on the incidence of ventilator-associated pneumonia (n = 9). CI confidence interval, M-H Mantel-Haenszel test
Fig. 3 Effect on hospital mortality (n = 17). CI confidence interval, M-H Mantel-Haenszel test
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of asymmetry were significant for overall new infections
(odds ratio (OR) -2.30, 95 % CI -3.56, -1.05, P = 0.001;
Fig. 9) and hospital LOS (OR -3.32, 95 % CI -6.12, -0.52,
P = 0.024). However, the test for asymmetry was not sig-
nificant for any other outcome (VAP, P = 0.76; mortality,
P = 0.80; ICU LOS, P = 0.47; diarrhea, P = 0.18).
Discussion
To date, our systematic review and meta-analysis is the
largest and most updated evaluation of the overall effects
of probiotics in the critically ill. It is also the first to in-
clude an analysis of symbiotic (probiotic/fiber combina-
tions). Based on the analysis of 30 trials enrolling 2972
patients we demonstrated that probiotics are associated
with a significant reduction in ICU-acquired infections,
including VAP, which is the most common infectious
complication in the critically ill. This significant effect
on VAP is a new finding from our previous systematic
reviews. Further, the beneficial effect of probiotics on re-
duction of infections is stronger with the publication of
the new trials and the data no longer show a statistically
significant effect of heterogeneity on this endpoint. Des-
pite the probiotic effect of reducing infectious complica-
tions, this therapy did not influence ICU or hospital
mortality, although none of the trials were powered to
detect an effect on mortality. Overall, there was a ten-
dency towards a reduction in ICU LOS and probiotic
therapy did not influence other clinical endpoints such
as hospital LOS, and diarrhea. Statistical and clinical het-
erogeneity was observed for some endpoints, although
this was significant for the key endpoints of infectious
complications and VAP. In addition, publication bias for
overall infections and hospital LOS means that larger,
well-powered, and more definitive clinical trials are ur-
gently needed aimed to avoid these biases. Moreover,
subgroup analysis showed that those trials with lower
methodological quality exhibit the best treatment effect,
which is another issue indicating that larger, well-
designed studies are needed. Again, with the exception
of four trials, most of the included studies (n = 14) that
reported mortality had small sample sizes, and hence
were underpowered and inadequate to detect any clinic-
ally important treatment effects of probiotic therapy on
mortality. Moreover, the inferences we can make from
our current findings are further weakened, as rando-
mization was concealed in 30 % of trials, whereas
double-blinding was performed in 67 % of trials.
Over recent years, several systematic reviews and
meta-analyses have been conducted, although our meta-
analysis is the largest and most current to date, as it
contains the seven new suitable trials published since
the most recent comprehensive meta-analysis publication
on this topic, which focused on overall infections and
other outcomes (not primarily VAP) in 2012 [14]. Further,
these previous systematic reviews did not include analysis
of synbiotic therapy. Overall, we have examined several
Fig. 4 Effect of probiotics on diarrhea (n = 9). CI confidence interval, M-H Mantel-Haenszel test
Fig. 5 Effect of probiotics on antibiotic days (n = 4). CI confidence interval; WMD weighted mean difference
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Fig. 6 Subgroup analysis: effect on infections of synbiotics (n = 4) versus probiotics alone (n = 10). CI confidence interval, M-H Mantel-Haenszel test
Fig. 7 Subgroup analysis: effect of higher (n = 9) vs. lower mortality (n = 5) on infections. CI confidence interval, IV inverse variance
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relevant clinical outcomes in a heterogenous ICU patient
population, and therefore our results could be applied to a
broad group of critically ill patients with sepsis, trauma,
severe pancreatitis, or who have undergone surgery.
Specific to pancreatitis, concerns have been raised about
the safety of probiotic therapy following the 2008 trial,
Probiotic prophylaxis in patients with predicted severe
acute pancreatitis (PROPATRIA) [43], which showed that
Ecologic 641® given with fiber post-pyloric was associated
with higher mortality and bowel ischemia. This post-
pyloric method of administration was associated with an
increase in small bowel necrosis, which was subsequently
associated with death in a number of patients receiving
the prebiotic fiber/probiotic mixture. It is possible that the
post-pyloric administration of this fiber/multiple probiotic
strain mixture in patients with pancreatitis may carry
Fig. 8 Subgroup analysis: effect of higher (n = 6) vs. lower methodological scores (n = 8) on infections. CI confidence interval, M-H Mantel-Haenszel test
Fig. 9 Funnel plot of primary outcome (n = 14). Overall new infections (test for asymmetry, OR -2.30, 95 % CI -3.56, -1.05, P = 0.001). OR odds ratio
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significant risk and should likely be avoided [52]. Un-
fortunately, there were significant ethical and statistical
concerns raised about the conduct of the trial [53], limiting
the utility of the data. Further, more recently, a systematic
review and meta-analysis by Gou et al. [54] found
that probiotics had neither beneficial nor adverse effects
in patients with pancreatitis.
Despite the limitations of the PROPRIATA trial, it has
contributed to concerns around the safety of probiotic
administration in critical illness and limited the design
of larger-scale clinical trials and/or more routine clinical
administration of live probiotics. To address this, the
American Health Care Research and Quality (AHRQ)
agency reviewed and reported on the safety of probiotic
therapy in over 600 published clinical trials and case re-
ports [55]. It should be reassuring to future investigators
that the overall conclusion of the extensive AHRQ re-
port indicates that probiotic therapy in both adults and
pediatric populations was not been found to be associated
with any increased risk of infectious or other adverse
events in either healthy or ill patients. Importantly, their
report revealed a trend towards less adverse events in
probiotic-treated critically ill patients, although isolated
adverse effects of probiotic administration have been re-
ported [56]. In any case, careful and appropriate safety
monitoring in all future probiotic clinical trials should be
conducted.
Recent data indicate that infection during critical
illness continues to be a major challenge worldwide. A
multi-national ICU study of 14,414 patients in 1265
ICUs from 75 countries, revealed that 51 % of ICU pa-
tients were considered infected on the day of survey and
71 % were receiving antibiotics [57]. Of the infections in
this study, 64 % were of respiratory origin and the ICU
mortality rate in infected patients was more than twice
that of non-infected patients (25 % vs. 11 %, P < 0.001),
as was the hospital mortality rate (33 % infected vs. 15 %
non-infected, P < 0.001) [57].
Currently, VAP is the second most common nosoco-
mial infection in the USA and the most prevalent ICU-
acquired infection. Notwithstanding, its incidence is
highly variable depending on diagnostic criteria used to
identify this infectious complication. In fact, in 2015 Ego
et al. [58] reported that the incidence of VAP ranged
from 4 % to 42 % when using the six published sets of
criteria and from 0 % to 44 % when using the 89 combina-
tions of criteria for hypoxemia, inflammatory response,
bronchitis, chest radiography, and microbiologic findings.
In our systematic review we found that the incidence of
VAP ranged from 9 % [46] to 80 % [39]. Additionally,
the apparent effect of probiotics on VAP is largely
driven by the studies of Kotzampassi et al. [39] study and
the Zeng et al. [26]; both trials explain 45.5 % of the signal
and thus, provide an unstable estimate. Moreover, current
knowledge shows that VAP is associated with high cost
and poor clinical outcomes [59]. In 2002, Rello et al. [60]
demonstrated that VAP leads to an additional US$40,000
in hospital charges per patient, and recently it has
been suggested that the use of prophylactic probiotics
may be cost-effective for prevention of VAP from a hos-
pital perspective [61].
Probiotic therapy may prevent VAP and other infec-
tions by restoring non-pathogenic flora, which competes
with nosocomial pathogens inhibiting their overgrowth,
modulating local and systemic immune response, and
improving gut barrier function. However, in spite of
these protective effects the role of probiotics as a non-
pharmacological strategy in preventing VAP has previ-
ously been inconclusive. In 2010, Siempos et al. [12]
aggregated five probiotic trials demonstrating a reduction
in the incidence of VAP, whereas in 2012 Petrof et al. [14]
and subsequently Barraud et al. [13] and Wang et al. [15]
did not demonstrate any significant effect of probiotic
therapy on VAP. More recently, a Cochrane review of
probiotic therapy specifically for VAP [17], found with low
quality of evidence that probiotic therapy is associated
with a reduction in the incidence of VAP. Our current
systematic review demonstrates a significant treatment
effect of probiotics in reducing VAP and did not demon-
strate statistical heterogeneity, strengthening the signal
that this may be an effective therapy for VAP. Recently, a
Canadian survey [27] on the use of probiotics as a prophy-
lactic strategy for VAP showed that most Canadian ICU
pharmacists have used probiotics at least once, although
they do not routinely recommend probiotics for the pre-
vention of VAP.
Currently, a large number of clinical trials have dem-
onstrated that probiotics may reduce the incidence of
antibiotic-associated diarrhea and Clostridium difficile
infections, and systematic reviews have confirmed a
significant signal of benefit on reduction of diarrhea
and C. difficile-related colitis in all patients (not con-
fined to ICU patients) [62, 63]. Our results, when fo-
cused on ICU patients do not currently demonstrate a
treatment benefit of probiotics in preventing and treat-
ing diarrhea in the critically ill, including antibiotic-
associated diarrhea.
An interesting finding of our meta-analysis was a re-
duction in antibiotic use in those patients who received
probiotics. Nonetheless, only four trials [10, 21, 26, 48]
comprising 13 % of included studies reported duration
of antibiotic therapy as an outcome. In addition, the
study of Zeng et al. contributed to 90 % of the signal,
which is a very unstable estimate that weakens our find-
ing. Therefore, probiotics may shorten the duration of
antibiotic therapy, although the limited clinical trial data
available for this endpoint limits the strength of these
findings and further investigation of this effect is needed.
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We currently have a greater understanding about the
potential benefits of probiotics therapy in critical illness,
although much more data are needed. Subgroup analysis
found that certain strains such as L. plantarum alone or
in combination was associated with a significant reduc-
tion in overall infections, although the test for subgroup
differences was not significant (P = 0.21). Certain spe-
cific biological properties have been described for L.
plantarum, including an ability to prevent adhesion of
pathogens to the intestinal epithelium secondary to
the production of adhesins, enolase, and phosphoglyc-
erate kinase on the bacterial surface [64, 65]. These
mechanisms may be crucial to reduction of bacterial
translocation and modulation of local inflammatory
response, and therefore the effect of this strain on
systemic infectious complications. Interestingly, pro-
biotics alone had a greater effect than synbiotics on
infections, although the difference between these sub-
groups was not significant (P = 0.98) and more data
on the specific effects of different prebiotic fibers are
needed. Finally, future trials also need to focus on
evaluating the changes in the microbiome following
critical illness and the effect of probiotic or synbiotics
on restoring a healthy microbiome in treated patients
[66]. Recent advances in microbiome sequencing technol-
ogy (16 s rRNA) in the last few years have resulted in an
unprecedented growth in the amount of sequence data
that can be collected at a previously unattainable low cost
[66]. Thus, if we speculate that a specific probiotic or syn-
biotic therapy can be used to treat dysbiosis (a patho-
logical change in the patient’s bacterial flora) and restore a
healthy microbiome, we need to evaluate this with the
new accessible microbiome analysis techniques currently
available. This may help us target probiotic or probiotic
mixtures in the future and increase the personalization
of care.
The strength of this current systematic review includes
the use of several methods to reduce bias (comprehensive
literature search, duplicate data abstraction, specific cri-
teria for searching and analysis), and the analysis of rele-
vant clinical outcomes in the critically ill. However, several
important limitations in drawing strong treatment infer-
ences are present. These include the significant potential
for publication bias for the infection and hospital LOS
outcomes, and the small numbers of trials included in
subgroup analyses. In addition, the variety of probiotic
strains, wide range of daily doses, and length of adminis-
tration of probiotic therapy among the different trials
weaken any possible clinical conclusions and recom-
mendations. We were also unable to perform subgroup
analysis for all clinical outcomes due to the limited num-
ber of studies evaluating each endpoint.
Based on our current data, there is not currently suffi-
cient evidence to make a final strong recommendation for
probiotics to be utilized in the prevention of infections,
including VAP, in the critically ill. However, our current
guideline recommendations suggest that probiotics should
be considered to improve outcome in critically ill patients
[19]. Future trials continue to need to address questions
about timing, daily dose, and duration of therapy, which
still remain unanswered.
Conclusion
In the largest systematic review and meta-analysis of
probiotics to date, we demonstrated that in 30 trials en-
rolling 2972 patients, probiotics significantly reduced the
incidence of infectious complications, including new epi-
sodes of VAP in critically ill patients. This finding is lim-
ited by clinical heterogeneity and potential publication
bias for the overall infection outcome. This precludes a
more meaningful statistical conclusion of the efficacy of
probiotic therapy on overall infections and potentially
the prevention of VAP in critical illness. Moreover,
according to our findings probiotics has been demon-
strated to be more effective in those trials with higher
mortality in the control group. Probiotic therapy with L.
plantarum currently demonstrates the most significant
effect on the reduction of infections. Overall, the variety
of strains, wide range of daily doses, and length of ad-
ministration of probiotics weakens the strength of our
conclusion. Certainly, additional large-scale, adequately
powered, well-designed clinical trials, aimed at confirm-
ing our observations, are needed and warranted.
Key messages
 Critical illness is characterized by a loss of
commensal flora and an overgrowth of potentially
pathogenic bacteria, leading to a high susceptibility
of nosocomial infections
 Probiotics are living non-pathogenic microorganisms,
which may protect the gut barrier, attenuate pathogen
overgrowth, decrease bacterial translocation and
prevent infection in ICU patients
 Probiotic use in the ICU remains widespread and
controversial, current guidelines are not conclusive,
and a significant number of new trials of probiotics
have been published recently, which requires a
current and comprehensive systematic analysis of
probiotic and synbiotic therapy in critically ill patients
 Probiotics were associated with a significant
reduction in infections and a significant reduction in
the incidence of ventilator-associated pneumonia
(VAP) was found in critically ill patients receiving
probiotics alone versus synbiotic mixtures,
demonstrating the greatest improvement in
infectious outcome, limited synbiotic trial data are
currently available
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 Currently, clinical heterogeneity and potential
publication bias reduce strong clinical
recommendations and indicate further high-quality
clinical trials are needed to conclusively prove
these benefits
 Probiotics shows promise for the reduction of
infections, including VAP in critical illness, and
should be considered in critically ill patients
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